Compare Gilead Sciences, Inc. (GILD) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs PPG Industries, Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.72 (market cap $163.51B), while PPG Industries, Inc. trades at $118.47 (market cap $25.70B). The key difference: Gilead Sciences, Inc. is far larger — about 6.4× PPG Industries, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | PPG | |
|---|---|---|
Market Cap | $163.51B | $25.70B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $131.56 |
52-Week Low | $108.22 | $94.34 |
Enterprise Value | $178.05B | $31.81B |
Dividend Yield | 2.49% | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
PPG Industries trades at $117.77, up 2.7% today, with a bullish technical signal and strong fundamentals including a 9.83% net margin and 21.09% ROE. Recent earnings beat expectations in Q1 2026, and analyst consensus is a Buy with a $131.75 price target. The company maintains innovation momentum with new product launches in aerospace and marine coatings, supporting long-term growth prospects.
The outlook for PPG is positive, driven by earnings growth and strategic innovations, but risks include economic sensitivity and competitive pressures. Valuation metrics like a P/E of 16.52 suggest reasonable pricing, with upside potential if the company meets Q2 2026 EPS expectations of $2.25.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
